Clinical Reviews in Allergy & Immunology

, Volume 54, Issue 2, pp 331–343 | Cite as

Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies

  • Francesca Trentin
  • Mariele Gatto
  • Margherita Zen
  • Larosa Maddalena
  • Linda Nalotto
  • Francesca Saccon
  • Elisabetta Zanatta
  • Luca Iaccarino
  • Andrea Doria
Article
  • 234 Downloads

Abstract

To date, belimumab is the only biological drug approved for the treatment of patients with active refractory SLE. We compared and critically analyzed the results of 11 observational clinical-practice-based studies, conducted in SLE referral centers. Despite the differences in endpoints and follow-up duration, all studies remarked that belimumab provides additional benefits when used as an add-on to existing treatment, allowing a higher rate of patients to reach remission and to taper or discontinue corticosteroids. In the OBSErve studies, 2–9.6% of patients discontinued corticosteroids and 72–88.4% achieved a ≥ 20% improvement by physician’s judgment at 6 months. In Hui-Yuen’s study, 51% of patients attained response by simplified SRI at month 6. In Sthoeger’s study, 72.3% of patients discontinued corticosteroids and 69.4% achieved clinical remission by PGA after a median follow-up of 2.3 years. In the multicentric Italian study, 77 and 68.7% of patients reached SRI-4 response at months 6 and 12, respectively. In all the studies, disease activity indices decreased over time. Retention rates at 6, 9, and 12 months were 82–94.1, 61.2–83.3, and 56.7–79.2%, respectively. The main limitations of these studies include the lack of a control group, the short period of observation (6–24 months) and the lack of precise restrictions regarding concomitant medication management. This notwithstanding, these experiences provide a more realistic picture of real-life effectiveness of the drug compared with the randomized controlled clinical trials, where stringent inclusion/exclusion criteria and changes in background therapy could limit the inference of data to the routine clinical care.

Keywords

Systemic lupus erythematous Belimumab BLyS Drug survival Drug efficacy Real-life experience 

Notes

Funding

The Authors declare no funding support for this paper. Andrea Doria: GSK consultant fee less than $10,000.

References

  1. 1.
    Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, Atzeni F, Piccoli A, Todesco S (2006) Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 119(8):700–706.  https://doi.org/10.1016/j.amjmed.2005.11.034 CrossRefPubMedGoogle Scholar
  2. 2.
    Doria A, Gatto M, Zen M, Iaccarino L, Punzi L. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev 2014; 13(7):770–7, 777, DOI:  https://doi.org/10.1016/j.autrev.2014.01.055
  3. 3.
    Doria A, Gatto M, Iaccarino L, Punzi L (2015) Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. Lupus 24(4–5):507–515.  https://doi.org/10.1177/0961203314559087 CrossRefPubMedGoogle Scholar
  4. 4.
    Gatto M, Kiss E, Naparstek Y, Doria A (2014) In-/off-label use of biologic therapy in systemic lupus erythematosus. BMC Med 12(1):30.  https://doi.org/10.1186/1741-7015-12-30 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gatto M, Saccon F, Zen M, Bettio S, Iaccarino L, Punzi L, Doria A (2016) Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis. J Autoimmun 74:94–105.  https://doi.org/10.1016/j.jaut.2016.06.014 CrossRefPubMedGoogle Scholar
  6. 6.
    Houssiau FA, Doria A (2016) Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty? Ann Rheum Dis 75(2):321–322.  https://doi.org/10.1136/annrheumdis-2015-208312 CrossRefPubMedGoogle Scholar
  7. 7.
    Doria A, Cervera R, Gatto M, Chehab G, Schneider M (2017) The new targeted therapy in systemic lupus erythematosus: is the glass half-full or half-empty? Autoimmun Rev 16(11):1119–1124.  https://doi.org/10.1016/j.autrev.2017.09.006 CrossRefPubMedGoogle Scholar
  8. 8.
    Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, Ferraccioli G, Galeazzi M, Gatto M, Gerli R, Govoni M, Gremese E, Iuliano A, Mansutti E, Moroni G, Mosca M, Nalli C, Naretto C, Padovan M, Palma L, Raffiotta F, Roccatello D, Tincani A, Valesini G, Zen M, Doria A (2015) Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian multicentre registry. Clin Exp Rheumatol 33(4):449–456PubMedGoogle Scholar
  9. 9.
    Yan M, Brady JR, Chan B, Lee WP, Hsu B, Harless S et al (2001) Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 11(19):1547–1552CrossRefPubMedGoogle Scholar
  10. 10.
    Vugmeyster Y, Seshasayee D, Chang W, Storn A, Howell K, Sa S, Nelson T, Martin F, Grewal I, Gilkerson E, Wu B, Thompson J, Ehrenfels BN, Ren S, Song A, Gelzleichter TR, Danilenko DM (2006) A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathol 168(2):476–489.  https://doi.org/10.2353/ajpath.2006.050600 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Scholz JL, Crowley JE, Tomayko MM, Steinel N, O’Neill PJ, Quinn WJ 3rd et al (2008) BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A 105(40):15517–15522.  https://doi.org/10.1073/pnas.0807841105 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, Lens S, Cachero TG, Finke D, Beermann F, Tschopp J (2001) Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med 194(11):1691–1697.  https://doi.org/10.1084/jem.194.11.1691 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Goenka R, Scholz JL, Sindhava VJ, Cancro MP (2014) New roles for the BLyS/BAFF family in antigen-experienced B cell niches. Cytokine Growth Factor Rev 25(2):107–113.  https://doi.org/10.1016/j.cytogfr.2014.01.001 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Khare SD, Sarosi I, Xia X-Z, McCabe S, Miner K, Solovyev I, Hawkins N, Kelley M, Chang D, van G, Ross L, Delaney J, Wang L, Lacey D, Boyle WJ, Hsu H (2000) Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A 97(7):3370–3375.  https://doi.org/10.1073/pnas.97.7.3370 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B, Metzger TE, Bixler SA, Hong YS, Ambrose CM, Mackay F, Morel L, Putterman C, Kotzin BL, Kalled SL (2005) BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 52(7):2080–2091.  https://doi.org/10.1002/art.21138 CrossRefPubMedGoogle Scholar
  16. 16.
    Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF (2013) Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus 22(9):873–884.  https://doi.org/10.1177/0961203313496302 CrossRefPubMedGoogle Scholar
  17. 17.
    Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44(6):1313–1319.  https://doi.org/10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S CrossRefPubMedGoogle Scholar
  18. 18.
    Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W (2008) Association of plasma B-lymphocyte stimulator (BLyS) levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 58(8):2453–2459.  https://doi.org/10.1002/art.23678 CrossRefPubMedGoogle Scholar
  19. 19.
    Collins CE, Gavin AL, Migone T-S, Hilbert DM, Nemazee D, Stohl W (2006) B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 8(1):R6.  https://doi.org/10.1186/ar1855 CrossRefPubMedGoogle Scholar
  20. 20.
    Meyer-Bahlburg A, Andrews SF, Yu KO, Porcelli SA, Rawlings DJ (2008) Characterization of a late transitional B cell population highly sensitive to BAFF mediated homeostatic proliferation. J Exp Med 205(1):155–168.  https://doi.org/10.1084/jem.20071088 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R (2004) Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20(6):785–798.  https://doi.org/10.1016/j.immuni.2004.05.010 CrossRefPubMedGoogle Scholar
  22. 22.
    Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721–731CrossRefPubMedGoogle Scholar
  23. 23.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918–3930.  https://doi.org/10.1002/art.30613 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Collins CE, Dall'Era M, Kan H, Macahilig C, Molta C, Koscielny V, Chang DJ (2016) Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med 3(1):e000118.  https://doi.org/10.1136/lupus-2015-000118 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Cortés J, Andreu JL, Calvo J, García-Aparicio AM, Coronell CG, Díaz-Cerezo S (2014) Evaluation of use of Belimumab in clinical practice settings (observe study) in Spain: health resource utilization and labour absenteeism. Value Health 17(7):A534.  https://doi.org/10.1016/j.jval.2014.08.1703 CrossRefPubMedGoogle Scholar
  26. 26.
    Schwarting A, Schroeder JO, Alexander T, Schmalzing M, Fiehn C, Specker C, Perna A, Cholmakow-Bodechtel C, Koscielny VB, Carnarius H (2016) First real-world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: results from the OBSErve Germany study. Rheumatol Ther 3(2):271–290.  https://doi.org/10.1007/s40744-016-0047-x CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Touma Z, Sayani A, Pineau CA, Fortin I, Matsos M, Ecker GA, Chow A, Iczkovitz S (2017) Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study. Rheumatol Int 37(6):865–873.  https://doi.org/10.1007/s00296-017-3682-9 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Hui-Yuen JS, Reddy A, Taylor J, Li X, Eichenfield AH, Bermudez LM, Starr AJ, Imundo LF, Buyon J, Furie RA, Kamen DL, Manzi S, Petri M, Ramsey-Goldman R, van Vollenhoven RF, Wallace DJ, Askanase A (2015) Safety and efficacy of belimumab in systemic lupus erythematosus academic clinical practices. J Rheumatol 42(12):2288–2295.  https://doi.org/10.3899/jrheum.150470 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Andreoli L, Reggia R, Pea L, Frassi M, Zanola A, Cartella S, Franceschini F, Tincani A (2014) Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients. Isr Med Assoc J 16(10):651–653PubMedGoogle Scholar
  30. 30.
    Scheinberg M, Golmia R (2014) Real life experience on the effect of Belimumab in patients with active systemic lupus. SpringerPlus 3(1):758.  https://doi.org/10.1186/2193-1801-3-758 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Scheinberg M, de Melo FF, Bueno AN, Costa CM, de Azevedo Bahr ML, Reis ER (2016) Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients. Clin Rheumatol 35(7):1719–1723.  https://doi.org/10.1007/s10067-016-3268-z CrossRefPubMedGoogle Scholar
  32. 32.
    Iaccarino L, Bettio S, Reggia R, Zen M, Frassi M, Andreoli L, Gatto M, Piantoni S, Nalotto L, Franceschini F, Larosa M, Fredi M, Punzi L, Tincani A, Doria A (2017) Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res (Hoboken) 69(1):115–123.  https://doi.org/10.1002/acr.22971 CrossRefGoogle Scholar
  33. 33.
    Sthoeger Z, Lorber M, Tal Y, Toubi E, Amital H, Kivity S, Langevitz P, Asher I, Elbirt D, Agmon Levin N (2017) Anti-BLyS Treatment of 36 Israeli Systemic Lupus Erythematosus Patients. Isr Med Assoc J 19(1):44–48PubMedGoogle Scholar
  34. 34.
    Iaccarino L, Andreoli L, Bocci EB, Bortoluzzi A, Ceccarelli F, Conti F, De Angelis R, De Marchi G, De Vita S, Di Matteo A, Emmi G, Emmi L, Gatto M, Gerli R, Gerosa M, Govoni M, Larosa M, Meroni PL, Mosca M, Pazzola G, Reggia R, Saccon F, Salvarani C, Tani C, Zen M, Frigo AC, Tincani A, Doria A (2017) Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J AutoimmunGoogle Scholar
  35. 35.
    Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Hearth-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP, OC-SELENA Trial (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353(24):2550–2558.  https://doi.org/10.1056/NEJMoa051135 CrossRefPubMedGoogle Scholar
  36. 36.
    Bertsias G, Ioannidis JPA, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, Isenberg D, Kallenberg CG, Khamashta M, Piette JC, Schneider M, Smolen J, Sturfelt G, Tincani A, van Vollenhoven R, Gordon C, Boumpas DT, Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67(2):195–205.  https://doi.org/10.1136/ard.2007.070367 CrossRefPubMedGoogle Scholar
  37. 37.
    Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 61(9):1143–1151.  https://doi.org/10.1002/art.24698 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, Kantor J, Kim E, Militello G, McGinnis K, Richardson S, Treat J, Vittorio C, Van Voorhees A, Werth VP (2005) The CLASI (cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythematosus. J Investig Dermatol 125(5):889–894.  https://doi.org/10.1111/j.0022-202X.2005.23889.x CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL (2009) Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68(6):954–960.  https://doi.org/10.1136/ard.2007.084459 CrossRefPubMedGoogle Scholar
  40. 40.
    Gladman DD, Ibanez D, Systemic Lupus UMB (2002) Erythematosus Disease Activity Index 2000. J Rheumatol 29(2):288–291PubMedGoogle Scholar
  41. 41.
    Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Kalunian K, Nived O, Petri M, Sanchez-Guerrero J, Snaith M, Sturfelt G (1997) The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 40(5):809–813.  https://doi.org/10.1002/art.1780400506 CrossRefPubMedGoogle Scholar
  42. 42.
    Gatto M, Iaccarino L, Zen M, Doria A (2017) When to use belimumab in SLE. Expert Rev Clin Immunol 13(8):737–740.  https://doi.org/10.1080/1744666X.2017.1324784 CrossRefPubMedGoogle Scholar
  43. 43.
    Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R (2003) The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis 62(2):168–171.  https://doi.org/10.1136/ard.62.2.168 CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Lenert A, Lenert P (2015) Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther 9:333–347 ReviewCrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Krystufková O, Vallerskog T, Helmers SB, Mann H, Putová I, Belácek J, Malmström V, Trollmo C, Vencovsky J, Lundberg IE (2009) Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 68(6):836–843.  https://doi.org/10.1136/ard.2008.091405 CrossRefPubMedGoogle Scholar
  46. 46.
    Xin G, Shi W, Xu LX, Su Y, Yan LJ, Li KS (2013) Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol 26(4):683–690.  https://doi.org/10.5301/jn.5000218 CrossRefPubMedGoogle Scholar
  47. 47.
    Kannel K, Alnek K, Vahter L, Gross-Paju K, Uibo R, Kisand KV (2015) Changes in blood B cell-activating factor (BAFF) levels in multiple sclerosis: a sign of treatment outcome. PLoS One 10(11):e0143393.  https://doi.org/10.1371/journal.pone.0143393 CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, Nocturne G, Gandolfo S, Isola M, Mariette X (2015) Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology (Oxford) 54(12):2249–2256.  https://doi.org/10.1093/rheumatology/kev257 Google Scholar
  49. 49.
    Quartuccio L, Salvin S, Corazza L, Gandolfo S, Fabris M, De Vita S (2016) Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren’s syndrome: follow-up after the end of the phase II open-label BELISS study. Clin Exp Rheumatol 34(2):311–314PubMedGoogle Scholar
  50. 50.
    Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, Wildman HF, Wood TA, Whitfield ML, Spiera RF Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis RheumatolGoogle Scholar
  51. 51.
    Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, Wilson B, Molta C, Roth D, Gordon D (2016) Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus 25(7):699–709.  https://doi.org/10.1177/0961203315625119 CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Zen M, Iaccarino L, Gatto M, Bettio S, Nalotto L, Ghirardello A, Punzi L, Doria A (2015) Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 74(12):2117–2122CrossRefPubMedGoogle Scholar
  53. 53.
    Zen M, Iaccarino L, Gatto M, Bettio S, Saccon F, Ghirardello A, Punzi L, Doria A (2017) The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. Ann Rheum Dis 76(3):562–565.  https://doi.org/10.1136/annrheumdis-2016-210154 CrossRefPubMedGoogle Scholar
  54. 54.
    Zen M, Iaccarino L, Gatto M, Saccon F, Larosa M, Ghirardello A, Punzi L, Doria A (2018) Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 77(1):104–110.  https://doi.org/10.1136/annrheumdis-2017-211613 CrossRefPubMedGoogle Scholar
  55. 55.
    van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71(8):1343–1349.  https://doi.org/10.1136/annrheumdis-2011-200937 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of RheumatologyUniversity of PadovaPadovaItaly

Personalised recommendations